Status:
COMPLETED
Role of Gene Variation in Effectiveness of Gleevec Treatment
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Cancer
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study will examine DNA from cancer patients previously treated with Gleevec to look for a variation (mutation) of the ABCG2 gene that may render the drug less effective in certain patients. Gleev...
Detailed Description
ABCG2, also known as breast cancer resistance protein (BCRP), is an ATP-binding cassette (ABC) transporter that has been shown to confer resistance to several drugs, including mitoxantrone and topotec...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- In this retrospective study, all cancer patients enrolled on IRB approved clinical trials of Gleevec from both the National Cancer and outside institutions will be eligible, provided that they have consented in the original consent form.
- EXCLUSION CRITERIA:
- Not applicable.
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
End Date :
October 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00342056
Start Date
January 1 2005
End Date
October 1 2008
Last Update
May 25 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010
2
Katholieke Universiteit Leuven, U Hospitals UZ Gasthuisberg
Leuven, Belgium